Latest Product Launch News

Cluey Ltd reported a stable Q1 FY26 revenue of $7.4 million alongside its strongest-ever underlying EBITDA, as it accelerates investment in AI-driven educational products set to launch in 2026.

EZZ Life Science Holdings reported a 25% drop in Q1 receipts, driven by seasonal softness and campaign timing, while accelerating its US market entry and launching three new health supplements.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

First Graphene Limited has reported its strongest first quarter sales ever for its PureGRAPH products, alongside new product launches and strategic partnerships that position it at the forefront of advanced materials innovation.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

Terragen Holdings expands its probiotic product range into beef and lamb feedlots, secures key international approvals, and progresses large-scale trials while maintaining a $3 million cash reserve.

ImpediMed Limited reported a record A$3.6 million quarterly revenue and expanded its US hospital footprint with over 600 SOZO units installed. The launch of SOZO Pro targets new heart failure markets, while reimbursement coverage accelerates across US states.

GreenHy2 Limited has launched its PowerSafe Sodium-Ion Battery range tailored for Australian conditions, expanded into turnkey solar and battery solutions, and signed a strategic MOU with Skeleton Technologies to explore advanced energy storage in Australia.

Axiom Properties Limited reports strong growth in its PaySure division, launches a new Settlement Advance product, and secures $1 million in fresh capital as it prepares to rebrand as Axtec Limited.

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

L1 Group has completed its merger with Platinum Asset Management, forming a $16.9 billion investment powerhouse focused on stabilising funds under management and unlocking significant cost synergies.